Blood eosinophils as a marker of response to inhaled corticosteroids in COPD Source: Eur Respir J 2016; 47:1374-1382 Year: 2016
Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment Source: Eur Respir J 2006; 27: 964-971 Year: 2006
Minimal effect of inhaled corticosteroids (ICS) on blood eosinophil count in steroid-naïve COPD patients Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015
Pulmonary function test changes after cessation of inhaled corticosteroid therapy in asthma patients Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012
Patients with COPD prescribed inhaled corticosteroid in primary care – Time for re-assessment based on exacerbation rate and blood eosinophils? Source: Virtual Congress 2020 – Diagnosis and management of airways disease in primary care Year: 2020
Assessment of maximal airway response before and after inhaled corticosteriod treatment in new diagnosed asthma patients Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007
Cytokines concentrations in induced sputum of mild COPD patients. Correlation to clinical response to inhaled corticosteroids Source: Eur Respir J 2002; 20: Suppl. 38, 309s Year: 2002
High sputum eosinophils are associated with better response to inhaled corticosteroids in asthmatic patients Source: Eur Respir J 2002; 20: Suppl. 38, 113s Year: 2002
Suppression of F ENO with observed inhaled corticosteroid therapy in severe asthma: is it a useful test in clinical practice? Source: ERJ Open Res, 5 (4) 00123-2019; 10.1183/23120541.00123-2019 Year: 2019
Monitoring of inflammatory changes in patients with bronchial asthma before and after oral corticosteroid treatment Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008
Lung function changes over time following withdrawal of inhaled corticosteroids in patients with severe COPD Source: Eur Respir J 2016; 47: 651-654 Year: 2016
Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids Source: International Congress 2015 – New data on established treatments for COPD Year: 2015
Association between blood eosinophil count and exacerbation risk in patients with asthma receiving medium- or high-dosage inhaled corticosteroids Source: International Congress 2017 – Biomarker-based asthma control Year: 2017
The interrelationship of the inflammatory markers in blood and sputum of stable COPD patients before and after treatment with inhaled steroids and N-acetylcysteine Source: Eur Respir J 2003; 22: Suppl. 45, 281s Year: 2003
Smoking, sputum cell counts, diffusion capacity and hyperinflation predict beneficial effects of long-term inhaled corticosteroids (ICS) on FEV1-decline in patients with mild-to-moderate COPD Source: Annual Congress 2010 - COPD: management Year: 2010
Low adherence to inhaled corticosteroids/long-acting ß2 -agonists and biologic treatment in severe asthmatics Source: ERJ Open Res, 6 (2) 00017-2020; 10.1183/23120541.00017-2020 Year: 2020
Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma? Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019
A treatment algorithm adjusting oral corticosteroid using blood eosinophils reduces exacerbations and improves asthma control, in difficult asthmatics Source: International Congress 2016 – Systemic biomarkers Year: 2016
Reducing the dose of inhaled corticosteroids (ICS) under therapy with montelukast in stable asthma: effects on lung function and inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001
Blood eosinophils do not predict inhaled budesonide response in bronchiectasis Source: Eur Respir J, 56 (3) 2002210; 10.1183/13993003.02210-2020 Year: 2020